Tuesday, April 29, 2025

Aurigene Pharmaceutical Services Ltd. introduces Aurigene.AI™, an artificial intelligence (AI) and machine learning (ML) assisted drug discovery platform

Related stories

Accenture Debuts AI Tool for Seamless Agent Collaboration

Accenture has unveiled 'Trusted Agent Huddle,' a pioneering solution...

Sumo Logic Unifies and Delivers Intelligent Security Ops

New innovations across AI, automation, and integrated threat intelligence...

Trend Micro Unveils AI Threat Detection with AWS, NVIDIA

Trend Micro Incorporated, a global cybersecurity leader, announced new...

IBM Unveils Autonomous Security with Agentic AI

New advanced AI capabilities help transform cybersecurity operations, driving...

Cribl and Palo Alto Networks Partner to Boost AI-driven SecOps Adoption

Partnership enables joint customers to upgrade from legacy SIEM...
spot_imgspot_img

Aurigene Pharmaceutical Services Limited , a contract research, development, and manufacturing services organization and a Dr. Reddy’s Laboratories company, introduces Aurigene.AI, an AI and ML-assisted platform for accelerating drug discovery projects from hit identification to candidate nomination.

Aurigene.AI combines advanced physics-based simulation, generative and predictive AI models, and CADD (Computer-Aided Drug Design) in one platform, allowing users to pick the appropriate algorithms for a given application. The modular platform also consists of a meticulously curated database of 180 million compounds and 1.6 million validated bioassay data points. This database is ever-expanding and serves as training data for the platform.

Aurigene.AI is hosted on Google Cloud, which offers a scalable infrastructure for handling large datasets and efficient computation while safeguarding client data confidentiality.

Also Read: Agilent Launches New Advanced Dilution System to Increase Lab Efficiency

Integrating AI and ML-based solutions with Aurigene’s core capabilities in chemical design, synthesis, and assessment in bioassays will facilitate faster development of novel therapeutics. Discovery scientists at Aurigene have validated the platform using a case study and demonstrated that the application of Aurigene.AI reduced the cycle time from chemical design to synthesis and testing by 35%.

Akhil Ravi, CEO, Aurigene Pharmaceutical Services Ltd., said, “We are committed to continually advancing our service experience and providing innovative end-to-end solutions to our global partners. Aurigene.AI is an important addition to our small molecule discovery offering and represents a data-driven approach to novel therapeutic development.”

Dr. Gayathri Ramaswamy, Global Head of Discovery Services, Aurigene Pharmaceutical Services Ltd., said, “The addition of AI and iterative machine learning capabilities to our core expertise in synthesizing and testing molecules will significantly reduce the DMTA cycle time in the discovery process. Aurigene.AI augments our core scientific capabilities in the small molecule discovery space and will serve as an efficient engine towards identifying a drug candidate.”

SOURCE: BusinessWire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img